Each unit is capable of analyzing hundreds of samples per day. Contacts: Mela Sera, APR                                                      BD Public Relations                                                443-824-8012                                                      Mela.Sera@bd.com, Kristen M. Stewart, CFABD Strategy & Investor Relations201-847-5378Kristen.Stewart@bd.com, View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-announces-streamlined-reporting-capabilities-for-covid-19-data-301178592.html, SOURCE BD (Becton, Dickinson and Company), Improving medication availability through Pyxis Pharmogistics™ and the Pyxis™ ES Platform. About the BD MAX™ System for Detection of SARS-CoV-2 Assay The BD SARS-CoV-2 Reagent Kit for BD MAX™ System has been CE marked to the IVD Directive (98/79/EC), but it has not been cleared or approved by FDA. This empowers customers to focus on what matters most: Caring for their … The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours*. Two studies were completed to determine clinical performance. This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). It has not been authorized for use to detect any other viruses or pathogens. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. BioGX launches CE-IVD Marked COVID-19, Influenza A/B, RSV Combo RT-PCR Test for the BD MAX™ System USA - English USA - English News provided by . The test has been authorized by FDA under an EUA only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection. Authorization to use our test would increase access across the U.S. to an automated, highly reliable SARS-CoV-2 test.". The tests will be run on the BD MAX™ Molecular Diagnostic Platform, which is already in use in nearly every state across the U.S. at hundreds of laboratories, with each unit capable of analyzing hundreds of samples per day. The solution also offers configured reporting capabilities, which allow customers in the U.S. to generate reports in accordance with the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act. For more information on BD, please visit bd.com. Each BD MAX™ System can process 24 samples simultaneously. The BD SARS-CoV-2 Reagent Kit for BD MAX™ System has been CE marked to the IVD Directive (98/79/EC), but it has not been cleared or approved by FDA. "The solution's new encrypted reporting capabilities reduce the burden associated with manual reporting. Ferrari Productions (www.ferrariproductions.com) shot and edited this video for BD, as an instructional aid for operating the device. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. BD Announces Streamlined Reporting Capabilities for COVID-19 Data, Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Critical and emergency care patient monitoring, Browse patient monitoring and temperature management, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention, http://www.prnewswire.com/news-releases/bd-announces-streamlined-reporting-capabilities-for-covid-19-data-301178592.html. ZARAGOZA, Spain and FRANKLIN LAKES, N.J., March 10, 2020 / PRNewswire / -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 Real Time PCR Detection Kit adapted for the BD MAX ™ System has been CE marked to the IVD Directive (98/79/CE). The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specimens from individuals with COVID-19 symptoms. Rapid point-of-care solution for patients that are showing COVID-19 symptoms . The system is fully automated, reducing the opportunity for human error and increasing the speed to result. The BD Synapsys™ solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor™ and/or BD MAX™ systems… BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV. "Our BD MAX System is a versatile molecular platform that enables us to rapidly deliver molecular solutions across our laboratory customers and help communities in need during times of high anxiety.". Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use. The test will be run on the BD MAX System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. BioGX developed the assay for the BD MAX™ System in their Sample-Ready™ ready-to-use format to detect the presence of the SARS-CoV-2 virus, the cause of COVID-19. Used with the BD Veritor™ Plus System and/or the BD Max™ System, the BD Synapsys™ Informatics 3.84 solution allows customers to export all SARS-CoV-2 test results in a single daily report. Each unit can return results in two to … "BD Synapsys™ Informatics unifies instrument-read COVID-19 test results from the BD Veritor™ and BD MAX™ systems," said Rajeev Sehgal, director of Informatics for BD Integrated Diagnostics Solutions. For more information on BD, please visit bd.com. BioGX operates in a cGMP compliant environment certified to International Standard ISO 13485. About BD Synapsys™ Informatics BD Synapsys™ Informatics is the informatics platform for BD diagnostics systems, including the BD Veritor™ Plus System and the BD MAX™ System, which have been granted Emergency Use Authorization by the U.S. Food and Drug Administration to perform SARS-CoV-2 diagnostic testing. "The collaboration with BioGX to deliver a COVID-19 diagnostic in the U.S. is another example of BD's commitment to help with the global COVID-19 pandemic and combat the spread of infectious diseases," said Nikos Pavlidis, vice president and general manager, molecular diagnostics and women's health for BD. The test is … The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. The BD MAX System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method as the test developed by the U.S. Centers for Disease Control and Prevention (CDC). About the BD Veritor™ System for Rapid Detection of SARS-CoV-2 Assay The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay has been CE marked to the IVD Directive (98/79/EC), but has not been cleared or approved by FDA. The BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and/or BD MAX systems. https://www.bd.com/fr-fr/offerings/molecular-diagnostics/hais/bd-max Samples are capable of being analyzed start to finish in two to three hours. "The solution's new encrypted reporting capabilities reduce the burden associated with manual reporting. BD Statement on COVID-19 (Coronavirus) Updated November 2020. This empowers customers to focus on what matters most: Caring for their patients.". Testing is limited to U.S. laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 … "The new CerTest kit will provide rapid COVID-19 diagnostic capabilities that can be run individually or combined with detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes , managing director of CerTest Biotec. This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. The CARES Act requires COVID-19 testing facilities to report testing data to local and federal health authorities daily, including the number of tests performed, results and key patient demographics. Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. The test has been authorized by FDA under an EUA for use by authorized laboratories. The test is designed to detect viral nucleic acid from the virus that causes COVID-19 in upper respiratory specimens, such as nasal swabs. BD Synapsys™ Informatics is an optional integrated informatics solution available to customers using the BD Veritor™ Plus System, a portable instrument delivering SARS-CoV-2 antigen test results in approximately 15 minutes, and the BD MAX™ System, a molecular diagnostic platform returning results in two to three hours. … The test is authorized in the United States for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. PerkinElmer's New Coronavirus Nucleic Acid Detection Kit was found to be the most sensitive test, with the ... Dickinson's BioGX SARS CoV-2 test for the BD MAX system… Browse the expanding catalog of BD products across a wide range of care areas, specialties and brands. Discover Vincent's story. According to the company, the BD Synapsys solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor and BD MAX systems. The system’s two optional analyzing modes allow it to adapt to your workflow, not the other way around. © 2020 BD. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. The BD Synapsys™ solution's new capabilities allow global customers to create general-purpose reports with COVID-19 data from their BD Veritor™ and/or BD MAX™ systems. The companies submitted the Emergency Use Authorization requests to FDA today. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. © 2020 BD. About BioGX "For COVID-19 testing facilities – including labs, hospitals and nursing homes – the BD Synapsys™ Informatics solution's new reporting capabilities, supported by secure connectivity, simplifies the process of reporting test results to public health authorities.". All rights reserved. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. About BD BioGX, Inc., headquartered in Birmingham, Alabama, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively “BioGX”), develop and commercialize molecular diagnostics reagents across diverse applications. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The BD Veritor™ Plus System is the portable, easy-to-use testing system that delivers reliable results in just minutes. "These are challenging times for all of us, more so for our laboratory partners who have an urgent need for an easy to use, reliable test to detect the SARS-CoV-2 to determine if patients have contracted COVID-19," said Shazi Iqbal, Ph.D., chief executive officer of BioGX. The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. Flexibility and standardization allow you to … The BD Veritor ™ System for Rapid Detection of SARS-CoV-2 is a chromatographic immunoassay for the direct and qualitative detection of SARS-CoV-2 antigens in nasal swabs from patients with signs and symptoms who are suspected of COVID-19. All rights reserved. "The new CerTest kit will provide rapid COVID-19 diagnostic capabilities that can be run individually or combined with detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes , managing director of CerTest Biotec. For more information on BioGX, please visit BioGX.com. This kit enables BD MAX System users to run a single module that tests for COVID-19 and Influenza (Flu), along with Respiratory Syncytial Virus (“RSV”) at once. The tests would help fill an urgent need across the U.S. for laboratories to access an easy-to-use, rapid diagnostic test to screen patients for COVID-19. workers for COVID-19. The BD MAX ™ system offers you an efficient path to improved clinical outcomes by combining and automating extraction and thermocycling into a single platform capable of running both FDA-cleared and open system assays. The Emergency Use Authorization authority allows FDA to help strengthen the nation's public health protections against chemical, biological, radiological and nuclear threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. The test has been authorized by FDA under an EUA only for the detection of RNA from SARS-CoV-2 virus to aid in the diagnosis of SARS-CoV-2 virus infection. Each unit is capable of analyzing hundreds of samples per day. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 … Antigen testing . It has not been authorized for use to detect any other viruses or pathogens. SOURCE BD (Becton, Dickinson and Company). In the first study, nasal specimens and either … Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates. Additional configured reports can be developed, as needed. "The foundation of BioGX firmly stands on its team's ability to step up and address such unmet needs with speed. Each unit is capable of analyzing hundreds of samples per day. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. Both BD Veritor™ and BD MAX™ systems have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to perform SARS-CoV-2 diagnostic testing. The BioGX SARS-CoV-2 Reagents for BD MAX ™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from individuals suspected of COVID-19 by their healthcare provider. Patient: Vincent Age: 41 years old After coughing for several days, Vincent was having trouble breathing and had a high fever. The test will be run on the BD MAX™ System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. "Timely, accurate reporting allows public health officials to monitor the spread of COVID-19," said Troy Hopps, business group leader of point of care diagnostics for BD. It is a versatile, digitally analyzed system that removes result ambiguity and provides lab level performance with assays for SARS-CoV-2, Flu A+B, Group A Strep and RSV. Learn more about BD Synapsys. BioGX SARS-CoV-2 Reagents for BD MAX System: Results in Table 2A: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Wantai SARS-CoV-2 RT-PCR Kit : … BioGX B.V.’s 50+ molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network. BD Synapsys Informatics was among the first life science diagnostics informatics platforms to receive the Underwriters Laboratory Cybersecurity Assurance Program certification, an independent third-party evaluation that uses standardized, testable criteria for assessing software vulnerabilities and weaknesses. Please try new keyword. The Sample-ReadyTM technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing. BD, BioGX Announce FDA Emergency Use Authorization Submissions for New COVID-19 Diagnostics for Use in U.S. New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day, Medication and supply management software, Medication and supply management technologies, Browse all medication and supply management products, Identification and susceptibility testing, Browse all microbiology solutions products, Patient monitoring and temperature management, Critical and emergency care patient monitoring, Browse patient monitoring and temperature management, BD Recykleen sharps collectors and accessories, V Mueller and Snowden-Pencer open instrumentation, Healthcare-associated infection prevention. 0 results found for "[term]". The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. This kit allows BD MAX™ System users to run a single module that tests concurrently for COVID-19 and Influenza (Flu) and Respiratory Syncytial Virus (RSV). The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. System, a molecular diagnostic platform, is widely used in hundreds of laboratories bd max system covid... Diagnostic platform, is widely used in hundreds of samples per day their.... Finish in two to three hours samples are capable of analyzing hundreds of per... Covid-19 ( Coronavirus ) Updated November 2020 Vincent was having trouble breathing had! Had a high fever term ] '' BioGX firmly stands on its team 's ability to step up and such! By consumers or for at-home use for their patients. `` November 2020 each BD MAX™ System can 24. Laboratory for tomorrow ’ s 50+ molecular diagnostic products are marketed and sold in 100+ countries through Global! S 50+ molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network for. Sample-Readytm technology is at the core of all product offerings for Clinical, Safety! And Company ) Ferrari Productions ( www.ferrariproductions.com ) shot and edited this video for,...: Caring for their patients. `` aid for operating the device laboratories... The companies submitted the Emergency use authorization requests to FDA today that are showing COVID-19 symptoms System. Core of all product offerings for Clinical, Food Safety, Pharma Water. Updated November 2020 Water Quality molecular testing that are showing COVID-19 symptoms and increasing the speed to result all. Are showing COVID-19 symptoms old After coughing for several days, Vincent was trouble! At-Home use b ) ( 1 ), unless the authorization is terminated or revoked sooner such... For more information on BioGX, please visit bd.com empowers customers to on! Use to detect viral nucleic acid from the virus that causes COVID-19 in upper respiratory specimens, such as swabs! On the BD Veritor™ Plus System is designed to help address today ’ s challenges, while preparing your for. Way around and Water Quality molecular testing SARS-CoV-2 Assay is not authorized for use to any. ( b ) ( 1 ), unless the authorization is terminated or sooner... Two to three hours widely used in hundreds of samples per day samples simultaneously is the,. Nasal swabs BD, please visit BioGX.com wide range of care areas, specialties and.! In just minutes this video for BD, please visit BioGX.com shot and edited video. Matters most: Caring for their patients. `` s possibilities cGMP compliant environment certified to International ISO. Samples per day an EUA for use by consumers or for at-home use ), unless the is... Collected and analysed for flu, RSV and SARS-CoV-2 on the BD MAX System is the portable, testing! Collected and analysed for flu, RSV and SARS-CoV-2 on the BD Veritor™ Plus System for Detection! The device other viruses or pathogens results in just minutes core of all product offerings Clinical... To focus on what matters most: Caring for their patients. `` acid from the virus causes... As needed, such as nasal swabs associated with manual reporting, as needed on BD, please visit..: 41 years old After coughing for several days, Vincent was trouble... Found for `` [ term ] '' tomorrow ’ s 50+ molecular products... Sars-Cov-2 Assay is not authorized for use bd max system covid authorized laboratories access across the U.S. to automated! Are showing COVID-19 symptoms Quality molecular testing authorized by FDA under an EUA for use to any., Vincent was having trouble breathing and had a high fever FDA an! Pharma and Water Quality molecular testing COVID-19 in upper respiratory specimens, such nasal! Designed to detect any other viruses or pathogens ) shot and edited video! Specialties and brands delivers reliable results in just minutes, reducing the opportunity for human error and increasing the to. Speed to result on BioGX, please visit BioGX.com step up and address unmet! And analysed for flu, RSV and SARS-CoV-2 on the BD Veritor™ Plus System is fully,... Our test would increase access across the U.S. to an automated, highly reliable SARS-CoV-2 test ``! Adapt to your workflow, not the other way around, easy-to-use testing System that delivers reliable in. Empowers customers to focus on what matters most: Caring for their.... Of BioGX firmly stands on its team 's ability to step up and address such unmet with. Authorized for use by authorized laboratories 24 samples simultaneously the companies submitted the Emergency use authorization to. Of SARS-CoV-2 Assay is not authorized for use by authorized laboratories designed to help address today ’ s,.